Bioavailability of Fish Oils: Emulsified Versus Capsular Triglyceride

NCT ID: NCT01488747

Last Updated: 2018-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this investigation is to determine the relative percentage and rate of incorporation of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and total omega-3 (n-3) fatty acids after ingestion of 4 emulsified flavored triglyceride fish oil supplements versus an encapsulated triglyceride in defined plasma lipid pools.

The primary endpoints to be evaluated include the fatty acid composition of plasma lipids before and after consumption of a single dose of emulsified triglyceride based fish oil and triglyceride of similar n-3 compositions in capsule form. The investigators will measure changes in plasma phospholipid, and chylomicron fatty acids.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Adults

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Coromega Omega-3 Squeeze

5.03 g

Group Type EXPERIMENTAL

Coromega Omega-3 Squeeze

Intervention Type DIETARY_SUPPLEMENT

660 mg EPA, 434 mg DHA

Coromega Nectar

12.22 g

Group Type EXPERIMENTAL

Coromega Nectar

Intervention Type DIETARY_SUPPLEMENT

660 mg EPA, 436 mg DHA

Barleans Swirl

17.45 g

Group Type EXPERIMENTAL

Barleans Swirl

Intervention Type DIETARY_SUPPLEMENT

660 mg EPA, 660 mg DHA

Nordic Omega-3 Softgel

4 softgels

Group Type ACTIVE_COMPARATOR

Nordic Omega-3 Softgel

Intervention Type DIETARY_SUPPLEMENT

660 mg EPA, 440 mg DHA

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coromega Omega-3 Squeeze

660 mg EPA, 434 mg DHA

Intervention Type DIETARY_SUPPLEMENT

Coromega Nectar

660 mg EPA, 436 mg DHA

Intervention Type DIETARY_SUPPLEMENT

Barleans Swirl

660 mg EPA, 660 mg DHA

Intervention Type DIETARY_SUPPLEMENT

Nordic Omega-3 Softgel

660 mg EPA, 440 mg DHA

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adults ages 18 to 60.
2. Body mass index between 22 and 32 kg/m2.
3. Medical history (interview) demonstrating good health.
4. Nonsmoker.
5. Consumption of a typical American diet with no unusual dietary habits.
6. Willingness to comply with the study protocol.
7. Low reported n-3 intake (\<100 mg/d) on the Omega-3 Checklist

Exclusion Criteria

1. Any active, uncontrolled medical problem.
2. Consumption of essential fatty acid supplements within the past 6 months.
3. Use of lipid lowering drugs.
4. Fish consumption greater than 1 fish meal per week
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

USDA Grand Forks Human Nutrition Research Center

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Susan Raatz, PhD, RD

Role: PRINCIPAL_INVESTIGATOR

USDA Grand Forks Human Nutrition Research Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

USDA Grand Forks Human Nutrition Research Center

Grand Forks, North Dakota, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Raatz SK, Redmon JB, Wimmergren N, Donadio JV, Bibus DM. Enhanced absorption of n-3 fatty acids from emulsified compared with encapsulated fish oil. J Am Diet Assoc. 2009 Jun;109(6):1076-81. doi: 10.1016/j.jada.2009.03.006.

Reference Type BACKGROUND
PMID: 19465191 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ars.usda.gov/main/site_main.htm?modecode=54-50-00-00

USDA Grand Forks Human Nutrition Research Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GFHNRC023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

An Evaluation of Omega-3 Fatty Acid
NCT03017651 COMPLETED PHASE1